TWI907439B - 核酸脂質粒子疫苗 - Google Patents

核酸脂質粒子疫苗

Info

Publication number
TWI907439B
TWI907439B TW110121263A TW110121263A TWI907439B TW I907439 B TWI907439 B TW I907439B TW 110121263 A TW110121263 A TW 110121263A TW 110121263 A TW110121263 A TW 110121263A TW I907439 B TWI907439 B TW I907439B
Authority
TW
Taiwan
Prior art keywords
sequence
rbd
cov
sars
mrna
Prior art date
Application number
TW110121263A
Other languages
English (en)
Chinese (zh)
Other versions
TW202214296A (zh
Inventor
河岡義裕
今井正樹
山吉誠也
石井健
小檜山康司
難波栄子
岡竜也
戸塚幸
城内直
小野寺宜郷
武下文彦
鈴木貴
丹羽貴子
小泉誠
中村健介
Original Assignee
日商第一三共股份有限公司
國立大學法人東京大學
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日商第一三共股份有限公司, 國立大學法人東京大學 filed Critical 日商第一三共股份有限公司
Publication of TW202214296A publication Critical patent/TW202214296A/zh
Application granted granted Critical
Publication of TWI907439B publication Critical patent/TWI907439B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
TW110121263A 2020-06-11 2021-06-10 核酸脂質粒子疫苗 TWI907439B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2020101420 2020-06-11
JP2020-101420 2020-06-11
JP2021-033278 2021-03-03
JP2021033278 2021-03-03

Publications (2)

Publication Number Publication Date
TW202214296A TW202214296A (zh) 2022-04-16
TWI907439B true TWI907439B (zh) 2025-12-11

Family

ID=78846062

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110121263A TWI907439B (zh) 2020-06-11 2021-06-10 核酸脂質粒子疫苗

Country Status (7)

Country Link
US (1) US20230248819A1 (https=)
EP (1) EP4166158A4 (https=)
JP (2) JP7672657B2 (https=)
KR (1) KR20230024261A (https=)
CN (1) CN115605221A (https=)
TW (1) TWI907439B (https=)
WO (1) WO2021251453A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12409219B2 (en) 2020-06-30 2025-09-09 Boost Biopharma, Inc. Recombinant polypeptides containing at least one immunogenic fragment and uses thereof
GB202119115D0 (en) * 2021-12-30 2022-02-16 Fondo Ricerca Medica S R I Vaccine
US20250109173A1 (en) * 2021-12-31 2025-04-03 Boost Biopharma, Inc. Recombinant polypeptides containing at least one immunogenic fragment and antibody fc region and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015005253A1 (ja) * 2013-07-08 2015-01-15 第一三共株式会社 新規脂質
US20190015501A1 (en) * 2014-04-23 2019-01-17 Modernatx, Inc. Nucleic acid vaccines

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020101420A (ja) 2018-12-21 2020-07-02 パナソニックＩｐマネジメント株式会社 透過度検知装置
CN110361853B (zh) 2019-08-16 2021-08-20 诚瑞光学(常州)股份有限公司 摄像光学镜头
US20210228707A1 (en) * 2020-01-28 2021-07-29 Modernatx, Inc. Coronavirus rna vaccines

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015005253A1 (ja) * 2013-07-08 2015-01-15 第一三共株式会社 新規脂質
US20190015501A1 (en) * 2014-04-23 2019-01-17 Modernatx, Inc. Nucleic acid vaccines

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
期刊 Wang F., et al., "An Evidence Based Perspective on mRNA-SARS-CoV-2 Vaccine Development", Med Sci Monit. 26: 2020 May 5 e924700-1–e924700-8. doi: 10.12659/MSM.924700 *

Also Published As

Publication number Publication date
JP2025094115A (ja) 2025-06-24
EP4166158A1 (en) 2023-04-19
KR20230024261A (ko) 2023-02-20
JPWO2021251453A1 (https=) 2021-12-16
CN115605221A (zh) 2023-01-13
EP4166158A4 (en) 2025-07-16
JP7672657B2 (ja) 2025-05-08
TW202214296A (zh) 2022-04-16
US20230248819A1 (en) 2023-08-10
WO2021251453A1 (ja) 2021-12-16

Similar Documents

Publication Publication Date Title
EP3901260A1 (en) Coronavirus vaccine
EP4147717A1 (en) Coronavirus vaccine
TWI907439B (zh) 核酸脂質粒子疫苗
US20250295755A1 (en) Mrna vaccine composition
EP4059515A1 (en) Nucleic acid lipid particle vaccine encapsulating hpv mrna
JP2026503718A (ja) エプスタイン・バーウイルスｍＲＮＡワクチン
KR102952315B1 (ko) 대상포진 mRNA 백신 및 이의 제조방법과 용도
JP2023546133A (ja) 汎ＲＡＳ ｍＲＮＡがんワクチン
KR102714014B1 (ko) 사스-코로나바이러스-2 델타 감염증 치료용 항체 mRNA 및 이를 포함한 조성물
WO2018168586A1 (ja) ボルナウイルスベクター及びその利用
KR102714027B1 (ko) 사스-코로나바이러스-2 델타 감염증 치료용 항체 mRNA 및 이를 포함한 조성물
US12397051B2 (en) Vaccine for use against coronavirus and variants thereof
Zheng et al. Porcine reproductive and respiratory syndrome virus nsp11 antagonizes broad antiviral effects of MCPIP1 by inducing interleukin-17 expression
US20240238404A1 (en) Influenza virus nucleic acid lipid particle vaccine
HK40087016A (en) Nucleic acid lipid particle vaccine
Zhou et al. The lncRNA GAS5-encoded micropeptide facilitates influenza virus replication through modulation of the Wnt/β-catenin signaling pathway
Robinson Investigating how SPLUNC1 mediates its anti-viral activity against Influenza A Viruses
HK40074627A (en) Nucleic acid lipid particle vaccine encapsulating hpv mrna
HK40104477A (en) Influenza virus nucleic acid lipid particle vaccine
TW202536184A (zh) 呼吸道融合病毒疫苗組合物及其用途
CN120676963A (zh) 使用一至终止减毒的SARS-CoV-2病毒的治疗
HK40061540A (en) Coronavirus vaccine
CN118632708A (zh) 基于piv5的冠状病毒疫苗及其使用方法
JP2024514875A (ja) タンパク質発現を増強できるポリヌクレオチド及びその使用
HK40061535A (en) Coronavirus vaccine